Literature DB >> 3462353

Evaluation of CA15/3 serum levels in breast cancer patients.

M Gion, R Mione, R Dittadi, S Fasan, A Pallini, G Bruscagnin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462353

Source DB:  PubMed          Journal:  J Nucl Med Allied Sci        ISSN: 0392-0208


× No keyword cloud information.
  7 in total

Review 1.  The use and potential of serum tumour markers, new and old.

Authors:  S E Bates
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

2.  Markers in breast cancer: does CEA add to the detection by CA 15.3?

Authors:  J C Delarue; H Mouriesse; F Dubois; S Friedman; F May-Levin
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

3.  The significance of determining CA 15-3 in the cytosol of breast cancer.

Authors:  K Kosian; C Bieglmayer; W Neunteufel; C Dadak
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Simple method for comparing reliability of two serum tumour markers in breast carcinoma.

Authors:  D P O'Brien; D B Gough; R Skehill; H Grimes; H F Given
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

5.  An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer.

Authors:  E H Cooper; M A Forbes; A K Hancock; J J Price; D Parker
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

6.  The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.

Authors:  M Gion; R Mione; O Nascimben; M Valsecchi; C Gatti; A Leon; G Bruscagnin
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

7.  Circulating CA 15-3 antigen levels in non-mammary malignancies.

Authors:  R Colomer; A Ruibal; J Genollà; L Salvador
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.